Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Vinorelbine Tartrate

FDA-approved product (injectable, injection), marketed as Navelbine, Vinorelbine Tartrate.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Vinorelbine Tartrate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cancer
  • Neoplasm

Indications ChEMBL records as approved, from FDA and DailyMed labels.

WHO therapeutic group
Vinca alkaloids and analogues
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli, K. pneumoniae and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA63.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli50.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae40.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis64.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Vinorelbine Tartrate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Vinorelbine Tartrate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Metronomic Chemotherapy in Elderly Non-fit Patients With Aggressive B-Cell Lymphomas

    NCT03161054 · start 2017-09-12

    Registered record
    Registry ID
    NCT03161054
    Conditions
    Aggressive Non-Hodgkin Lymphoma
    Interventions
    Prednisone; Vinorelbine; Etoposide; Cyclophosphamide; Rituximab
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2017-09-12
    Completion
    2021-06-21
    Enrolment
    21

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAggressive Non-Hodgkin Lymphoma
    InterventionPrednisone; Vinorelbine; Etoposide; Cyclophosphamide +1 more
    PhasePhase 2
    Registry statusCompleted

  • Dose-escalation Study of Intravenous Liposomal Vinorelbine Tartrate Injection in Patients With Advanced Malignancy

    NCT02925000 · start 2017-06-19

    Registered record
    Registry ID
    NCT02925000
    Conditions
    Cancer
    Interventions
    TLC178
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2017-06-19
    Completion
    2020-10-06
    Enrolment
    46

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCancer
    InterventionTLC178
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Oral Navelbine and Cisplatin Followed by Metronomic Oral Navelbine in Non-Small Cell Lung Cancer

    NCT02985203 · start 2016-11

    Registered record
    Registry ID
    NCT02985203
    Conditions
    Lung Neoplasm Malignant
    Interventions
    Vinorelbine Oral
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2016-11
    Completion
    2018-04
    Enrolment
    45

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLung Neoplasm Malignant
    InterventionVinorelbine Oral
    PhasePhase 2
    Registry statusTerminated

  • Systemic Chemotherapy Combined With Recombinant Human Adenovirus Type 5 and Endostatin Injections for Treatment Malignant Hydrothorax in NSCLC Patients

    NCT02579564 · start 2016-10

    Registered record
    Registry ID
    NCT02579564
    Conditions
    Malignant Hydrothorax; Non Small Cell Lung Cancer
    Interventions
    Gemcitabine; Vinorelbine; Paclitaxel; Pemetrexed; Oncorine; Endostar; Cisplatin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2016-10
    Completion
    2018-12
    Enrolment
    134

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalignant Hydrothorax; Non Small Cell Lung Cancer
    InterventionGemcitabine; Vinorelbine; Paclitaxel; Pemetrexed +3 more
    PhasePhase 3
    Registry statusUnknown

  • Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers

    NCT02892123 · start 2016-09-30

    Registered record
    Registry ID
    NCT02892123
    Conditions
    HER2-expressing Cancers
    Interventions
    ZW25 (Zanidatamab); Paclitaxel; Capecitabine; Vinorelbine; Tucatinib; Tucatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2016-09-30
    Completion
    2024-10-31
    Enrolment
    279

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHER2-expressing Cancers
    InterventionZW25 (Zanidatamab); Paclitaxel; Capecitabine; Vinorelbine +2 more
    PhasePhase 1
    Registry statusCompleted

  • PERS Genetic Model Assistant Decision-making System of Neoadjuvant Chemotherapy for Breast Cancer

    NCT03006614 · start 2016-04

    Registered record
    Registry ID
    NCT03006614
    Conditions
    Breast Cancer Model; Effects of Chemotherapy; Breast Cancer
    Interventions
    NVB; EPI; DDP; CAP; GEM; H; CTX; T
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2016-04
    Completion
    2023-03
    Enrolment
    320

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer Model; Effects of Chemotherapy; Breast Cancer
    InterventionNVB; EPI; DDP; CAP +4 more
    PhasePhase 3
    Registry statusUnknown

  • Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer

    NCT02492711 · start 2015-08-24

    Registered record
    Registry ID
    NCT02492711
    Conditions
    HER-2 Positive Breast Cancer; Metastatic Neoplasm
    Interventions
    Margetuximab; Trastuzumab; Physician's choice of chemotherapy.
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2015-08-24
    Completion
    2022-06-14
    Enrolment
    624

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHER-2 Positive Breast Cancer; Metastatic Neoplasm
    InterventionMargetuximab; Trastuzumab; Physician's choice of chemotherapy.
    PhasePhase 3
    Registry statusCompleted

  • the"Fuzheng" Therapy of TCM to Improve the Survival Quality of Early-stage NSCLC by Intervening the CTCs

    NCT02603003 · start 2015-06

    Registered record
    Registry ID
    NCT02603003
    Conditions
    Non-small Cell Lung Cancer(NSCLC)
    Interventions
    JinFuKang; Cisplatin; Pemetrexed
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2015-06
    Completion
    2019-09-01
    Enrolment
    218

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-small Cell Lung Cancer(NSCLC)
    InterventionJinFuKang; Cisplatin; Pemetrexed
    PhasePhase 1
    Registry statusCompleted

  • Phase II Trial of Oral Vinorelbine in Children With Recurrent or Progressive Unresectable Low-Grade Glioma

    NCT02197637 · start 2014-05

    Registered record
    Registry ID
    NCT02197637
    Conditions
    Low-Grade Glioma
    Interventions
    ORAL VINORELBINE
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2014-05
    Completion
    2020-10
    Enrolment
    39

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLow-Grade Glioma
    InterventionORAL VINORELBINE
    PhasePhase 2
    Registry statusCompleted

  • SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer

    NCT02299999 · start 2014-04-07

    Registered record
    Registry ID
    NCT02299999
    Conditions
    Metastatic Breast Cancer
    Interventions
    AZD2014; AZD4547; AZD5363; AZD8931; Selumetinib; Vandetanib; Bicalutamide; Olaparib; Anthracyclines; Taxanes; cyclophosphamide; DNA intercalators; Methotrexate; vinca alkaloids; Platinum based chemotherapies; Bevacizumab; Mitomycin C; Eribulin; MEDI4736
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2014-04-07
    Completion
    2025-12
    Enrolment
    1,460

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Breast Cancer
    InterventionAZD2014; AZD4547; AZD5363; AZD8931 +15 more
    PhasePhase 2
    Registry statusActive not recruiting

  • Eribulin Versus Vinorelbine in Subjects With Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes

    NCT02225470 · start 2013-09-26

    Registered record
    Registry ID
    NCT02225470
    Conditions
    HER2-Negative Breast Cancer; Triple Negative Breast Cancer; Breast Cancer; Cancer of Breast; Breast Tumors
    Interventions
    E7389 (Eribulin Mesylate); Vinorelbine injection
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2013-09-26
    Completion
    2018-06-22
    Enrolment
    530

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHER2-Negative Breast Cancer; Triple Negative Breast Cancer; Breast Cancer; Cancer of Breast +1 more
    InterventionE7389 (Eribulin Mesylate); Vinorelbine injection
    PhasePhase 3
    Registry statusCompleted

  • An Dose Escalation Trial of Oral BIBF 1120 in Combination With Intravenous Vinorelbine in Elderly Patients With Advanced Non Small Lung Cell Cancer - Stage IV (VENUS-1)

    NCT01684111 · start 2013-06

    Registered record
    Registry ID
    NCT01684111
    Conditions
    Carcinoma, Non-Small-Cell Lung
    Interventions
    BIBF 1120; Vinorelbine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2013-06
    Completion
    Not recorded
    Enrolment
    7

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCarcinoma, Non-Small-Cell Lung
    InterventionBIBF 1120; Vinorelbine
    PhasePhase 1
    Registry statusCompleted

  • Trastuzumab & Pertuzumab Followed by T-DM1 in MBC

    NCT01835236 · start 2013-03-03

    Registered record
    Registry ID
    NCT01835236
    Conditions
    Metastatic Breast Cancer
    Interventions
    Trastuzumab; Pertuzumab; Paclitaxel; Vinorelbine; T-DM1
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2013-03-03
    Completion
    2020-05-26
    Enrolment
    208

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Breast Cancer
    InterventionTrastuzumab; Pertuzumab; Paclitaxel; Vinorelbine +1 more
    PhasePhase 2
    Registry statusCompleted

  • Valproic Acid With Chemoradiotherapy for Non-Small-Cell Lung Cancer

    NCT01203735 · start 2011-02

    Registered record
    Registry ID
    NCT01203735
    Conditions
    Locally Advanced Inoperable Non-small-lung Cancer
    Interventions
    Valproic acid
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Unknown
    Start
    2011-02
    Completion
    2015-02
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLocally Advanced Inoperable Non-small-lung Cancer
    InterventionValproic acid
    PhasePhase 1 / Phase 2
    Registry statusUnknown

  • BIBW 2992 (Afatinib) and Vinorelbine in Japanese Patients With Advanced Solid Tumours

    NCT01214616 · start 2010-10-01

    Registered record
    Registry ID
    NCT01214616
    Conditions
    Neoplasms
    Interventions
    afatinib 20mg; afatinib 40mg; vinorelbine IV 25 or 20mg/m2
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2010-10-01
    Completion
    2013-05-01
    Enrolment
    17

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNeoplasms
    Interventionafatinib 20mg; afatinib 40mg; vinorelbine IV 25 or 20mg/m2
    PhasePhase 1
    Registry statusCompleted